Literature DB >> 15598590

EB-D fibronectin expression in squamous cell carcinoma of the head and neck.

Paulette Mhawech1, Pavel Dulguerov, Mounia Assaly, Carmen Ares, Abdelkarim S Allal.   

Abstract

ED-B fibronectin (ED-B FN), a glycoprotein involved in cell adhesion and migration, is expressed in fetal and neoplastic tissues and absent in their normal counterparts. The aim of this study is to evaluate the expression of this glycoprotein in relation to the histological and clinical data and to determine whether it has a prognostic value in patients with head and neck squamous cell carcinoma (HNSCC). Ninety-five cases were assessed for ED-B FN expression using immunohistochemistry. Positive ED-B FN expression was significantly associated with tumor grade (p=0.06) and primary tumor site (p=0.02). The larynx was the tumor site associated with the least ED-B FN expression. In univariate analysis, there was no association with disease-free survival (p=0.48), but the mean time to progression was clearly shorter in tumors with positive ED-B FN expression than in those with negative expression (6 vs. 11 months). Patients having tumors expressing the ED-B FN had a trend to a significant lower overall survival in the multivariate analysis (p=0.06). Our study showed that ED-B FN expression might have a prognostic value in patients with HNSCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15598590     DOI: 10.1016/j.oraloncology.2004.07.003

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  15 in total

1.  Theranostics for Breast Cancer Stem Cells.

Authors:  Woo Kyung Moon; Hoe Suk Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Synthesis and assessment of ZD2-(68Ga-NOTA) specific to extradomain B fibronectin in tumor microenvironment for PET imaging of pancreatic cancer.

Authors:  Songqi Gao; Jingcan Qin; Olga Sergeeva; Maxim Sergeev; Peter Qiao; Sarah Roelle; Norbert Avril; Zhenghong Lee; Yajuan Li; Zhengrong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

3.  Targeting Fibronectin for Cancer Imaging and Therapy.

Authors:  Zheng Han; Zheng-Rong Lu
Journal:  J Mater Chem B       Date:  2016-12-01       Impact factor: 6.331

Review 4.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer.

Authors:  Rajakishore Mishra
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

5.  Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.

Authors:  Yajuan Li; Zheng Han; Sarah Roelle; Aidan DeSanto; Rob Sabatelle; Rebecca Schur; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2017-10-25       Impact factor: 4.939

6.  Plasma and cellular fibronectin: distinct and independent functions during tissue repair.

Authors:  Wing S To; Kim S Midwood
Journal:  Fibrogenesis Tissue Repair       Date:  2011-09-16

7.  MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles.

Authors:  Yujin Sun; Hoe Suk Kim; Jinho Park; Mulan Li; Lianji Tian; YoonSeok Choi; Byung Ihn Choi; Sangyong Jon; Woo Kyung Moon
Journal:  Theranostics       Date:  2014-06-10       Impact factor: 11.556

8.  Fibronectin-guided migration of carcinoma collectives.

Authors:  Sandeep Gopal; Laurence Veracini; Dominique Grall; Catherine Butori; Sébastien Schaub; Stéphane Audebert; Luc Camoin; Emilie Baudelet; Agata Radwanska; Stéphanie Beghelli-de la Forest Divonne; Shelia M Violette; Paul H Weinreb; Samah Rekima; Marius Ilie; Anne Sudaka; Paul Hofman; Ellen Van Obberghen-Schilling
Journal:  Nat Commun       Date:  2017-01-19       Impact factor: 14.919

Review 9.  Migratory neighbors and distant invaders: tumor-associated niche cells.

Authors:  Jared Wels; Rosandra N Kaplan; Shahin Rafii; David Lyden
Journal:  Genes Dev       Date:  2008-03-01       Impact factor: 11.361

Review 10.  The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine.

Authors:  B Eyden
Journal:  J Cell Mol Med       Date:  2007-12-22       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.